An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial. (nature.com)

Authors: Li X … Auwerx J Journal: Nature Medicine Published: 2026-03-01 DOI: https://doi.org/10.1038/s41591-025-04169-6